

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Grueneberg et al.

Examiner: **To Be Assigned**

Art Unit: **1645**

Application No.: **10/574,416**

Filed: **March 31, 2006**

Title: **Retroviral Vectors For Delivery of
Interfering RNA**

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

02/24/2008


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it was submitted: (1) within three months of the filing date of a national application other than a continued prosecution application under §1.53(d); (2) within three months of the date of entry of the national stage as set forth in §1.491 in an international application; (3) before the mailing date of a first Office Action on the merits; or (4) before the mailing of a first Office Action after the filing of request for continued examination under §1.114.

In the event the first Office Action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



Karen I. Krupen, Reg. No. 34,647
Attorney for Applicant

sanofi-aventis U.S. Inc.
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4658
Telefax (908) 231-2626
sanofi-aventis Docket No. USAV2002/0187 US PCT

☒

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<div>Complete if Known</div> <div>Application Number 10/574,416</div> <div>Filing Date 03-31-2006</div> <div>First Named Inventor GRUENEBERG</div> <div>Group Art Unit 1645</div> <div>Examiner Name To Be Assigned</div> <div>Attorney Docket Number USAV2002/0187 - US - PCT</div>	
<div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>					
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Garden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

02/24/2008

Please type a plus sign (+) inside this box → ☒

PTO/SB/088 (10-95)

Approved for use through 10/31/99. CMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid GMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/574,416
		Filing Date	03-31-2006
		First Named Inventor	GRUENEBERG
		Group Art Unit	1645
		Examiner Name	To Be Assigned
		Attorney Docket Number	USAV2002/0187 - US - PCT
Sheet	2	of	2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.C./		DEVROE et al., Retrovirus-delivered siRNA, BMC Technology, Biomed Central, Aug. 28, 2002, pp. 1-5	
/K.C./		LIEBERMAN et al., Interfering with disease: opportunities and roadblocks to harnessing RNA interference, Trends in Molecular Medicine, Sept. 2003, Vol. 9, No. 9, pp. 397-403	
/K.C./		LIU et al., Short hairpin RNA and retroviral vector-mediated silencing of p53 in mammalian cells, Biochem. & Biophys. Res. Comm., Oct. 12, 2004, Vol. 324, No. 4, pp. 1173-1178	
/K.C./		MITTA et al., Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction, Nucleic Acids Research, Nov. 1, 2002, Vol. 30, No. 21, pp. E113.1 to E113.18	
/K.C./		TISCORNIA et al., A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA, PNAS, Vol. 100, No. 4, Feb. 18, 2004, pp. 1844-1848	
/K.C./		RUBINSON et al., A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference, Nature Genetics, Vol. 33, No. 3, March 2003, pp. 401-406	

Examiner Signature	/Kimberly Chong/	Date Considered	02/24/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231